Neomera BioLab
Neomera BioLab is building ORBIT™, a generative AI model specifically engineered for biologics discovery and design. The platform applies generative machine learning to explore vast sequence and structural spaces, enabling the design and optimization of novel therapeutic proteins and antibodies beyond conventional screening approaches. This computational strategy is intended to accelerate early-stage discovery for biopharmaceutical companies and research institutions.
- Drug Discovery & Therapeutics
- Artificial Intelligence
- Biotechnology
- Software Only
Funding
Founders
Founder details are not available yet.
Product
Problem
Biologics discovery and design rely heavily on iterative, time-intensive experimental workflows, with vast sequence and structural spaces that are difficult to explore systematically. This leads to slow development cycles, high costs, and low success rates in bringing novel therapeutic proteins and antibodies to market.
Solution
Neomera BioLab is building ORBIT™, a generative AI model specifically engineered for biologics. The platform leverages generative machine learning to design and optimize biological sequences with desired functional properties, reducing reliance on purely empirical screening. By learning from existing biologics data, ORBIT™ is intended to generate novel candidates, predict favorable characteristics, and support rational design of next-generation therapeutics.
Target Audience
Primary customers are biopharmaceutical companies and research institutions engaged in biologics discovery and development, particularly those focused on protein engineering and antibody therapeutics.
Features
- ORBIT™ generative AI architecture tailored for biological sequence modeling
- Ability to propose novel biologics candidates beyond conventional screening spaces
- Focus on therapeutic proteins and antibody design workflows
- Computational approach designed to accelerate early-stage discovery and optimization